Welcome : Guest

Brainstorm Cell Therapeutics, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Brainstorm Cell Therapeutics, Inc., which is principally involved in Biotechnology Business. Illustrated with 30 tables, the report showcases the company's recent news stories and events, key markets and market position as against its competitors operating in the industry.

Code: PCP-16612
Price: $1500
Company Type: Public
Pages: 32
Date: January 2016
Market Data Tables: 30

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Multiple Sclerosis......2
Table 1: Multiple Sclerosis Disease Occurrence by Type Worldwide (2014) - Percentage Breakdown by Volume for Begin MS, Primary Progressive MS, Relapsing-Remiting MS, and Secondary Progressive MS......2
Table 2: Multiple Sclerosis Patient Care Expenditure by Category Worldwide (2014) - Percentage Breakdown by Value for Adaptations, Ambulatory Care, Disease Modifying Drugs, Early Retirement, Hospital Inpatient Care, Informal Care, Prescription and OTC Drugs, Services, Sick-leave and Redused Working Time, and Tests......3
Table 3: No. of Tcelna (Imilecleucel-T) Secondary Progressive Multiple Sclerosis Patients by Category in the US (2014) - Percentage Breakdown for Primary Progressive MS Patients, Relapsing-Remitting MS Patients, and Secondary-Progressive MS Patients......4
Table 4: Therapeutic Drugs Market by Category Worldwide (2014) - Percentage Share Breakdown by Value Sales for Cancer/Onc./Hem., Cardiology, CNS, Dermatology, Diabetes, GI/Ulcer, Infectious Disease, Multiple Sclerosis, Ophthalmology, Respiratory, Rheumatology, Women's Health, and Others......5
Table 5: Speciality Pharmaceuticals Market by Category in the US (2014) - Percentage Share Breakdown by Value Sales for Anti-Coagulant, Growth Hormone, Hepatitis C, HIV/AIDS (incl oral solids), IVIG/Hemophilia, Macular Degeneration, Multiple Sclerosis, Oncology (incl. oral solids), Pulmonary Arterial Hypertension, Renal, Rheumatoid arthritis/Chrohn's, Transplant, and Others......6
Relapsing-Remitting Multiple Sclerosis (RRMS)......7
Table 6: Relapsing-Remitting Multiple Sclerosis (RRMS) Market by Region Worldwide (2015) - Percentage Share Breakdown by Volume for European Union (EU), US, Rest of World (RoW)......7
Parkinson's Disease......8
Table 7: Parkinson's Market by Type Worldwide (2015) - Percentage Breakdown by Volume for Mild, Moderate and Severe......8
Table 8: Population Affliected with Parkinson's by Age Group in the US (2015) - Percentage Share Breakdown for 65-69, 70-74, 75-79, 80-84 and 85+......9
Stem Cell Transplantation......10
Table 9: Adult Recipients (18+ years) Transplant Market by Cell Source in Japan (2014) - Percentage Share Breakdown by Volume for Bone Marrow, Cord Blood and Peripheral Blood Stem Cells......10
Table 10: Stem Cell Transplantation Market by Category for American Indian and Alaskan Natives in the US (2015) - Percentage Market Share Breakdown by Volume for Bone Marrow of Periperal Blood and Cord Blood......11
Table 11: Stem Cell Transplantation Market by Category for Asians in the US (2015) - Percentage Share Breakdown by Volume for Bone Marrow of Periperal Blood and Cord Blood......12
Table 12: Stem Cell Transplantation Market by Category for Black and African Americans in the US (2015) - Percentage Market Share Breakdown by Volume for Bone Marrow of Periperal Blood and Cord Blood......13
Table 13: Stem Cell Transplantation Market by Category for Native Hawalian and Other Pacific Islanders in the US (2015) - Percentage Share Breakdown by Volume for Bone Marrow of Periperal Blood and Cord Blood......14
Table 14: Stem Cell Transplantation Market by Category for Whites in the US (2015) - Percentage Share Breakdown by Volume for Bone Marrow of Periperal Blood and Cord Blood......15
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)......16
Table 15: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Acute Leukemia by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......16
Table 16: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Bone Marrow Failure by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......17
Table 17: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Leukemia by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......18
Table 18: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Leukemias by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......19
Table 19: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Lymphoma by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......20
Table 20: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Lymphoproliferative by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......21
Table 21: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Mixed Myelodysplastic and Myeloproliferative Syndromes (MDS/MPS) by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......22
Table 22: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Non-Malignant Disorders by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......23
Table 23: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Plasma Cell Disorders by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......24
Table 24: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Solid Tumors by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......25
Table 25: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Market by Category in Americas (2015) - Percentage Share Breakdown by Value for Acute Leukemia, Chronic Leukemia, Leukemias, Lymphoma, Lymphoproliferative, Mixed Myelodysplastic and Myeloproliferative Syndromes (MDS/MPS) and Others......26
Table 26: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Market by Category in Europe (2015) - Percentage Share Breakdown by Value for Acute Leukemia, Leukemias, Lymphoma, Lymphoproliferative, Mixed Myelodysplastic and Myeloproliferative Syndromes (MDS/MPS), Non-Malignant Disorders and Others......27
Multiple Sclerosis Therapeutics......28
Table 27: Market Shares of Leading Multiple Sclerosis Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for Biogen Idec, Novartis AG, Sanofi S.A., and Others......28
Table 28: Market Shares of Leading Therapeutic Providers (Alzheimer's Disease, Bone Diseases, Cardiology, CNS, Dermatology, Diabetes/Metabolic, Epilepsy, G.I./Ulcer, HBV/HCV, Infectious Disease, Multiple Sclerosis, Obesity, Onc./Hematology, Ophthalmology, Orphan Disease, Pain Management, Respiratory, Rheumatology, Sleep Disorders, Urinary Incont., and Women's Health) by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Biogen Idec, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Endo International Plc, F. Hoffmann-La Roche AG, Forest Laboratories, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Sanofi S.A., and Others......29
Relapsing-Remitting Multiple Sclerosis (RRMS)......30
Table 29: Market Shares of Leading Drug Brands for Relapsing-Remitting Multiple Sclerosis (RRMS) Worldwide (2015) - Percentage Breakdown by No. of Patients for Avonex, Betaseron, Copaxone, Gilenya, Laquinimod, Rebif, Tysabri, and Others......30
Table 30: Market Shares of Leading Drug Brands for Relapsing-Remitting Multiple Sclerosis (RRMS) Worldwide (2015) - Percentage Breakdown by Value for Avonex, Betaseron, Copaxone, Gilenya, Laquinimod, Rebif, Tysabri, and Others......31

4. RECENT INDUSTRY DEVELOPMENTS......32